Targets — browse / sort / filter (view)
Data license: CC BY 4.0 · Data source: apt-scout automated curation pipeline (E. Dohi, NCNP) — values harvested from public databases; raw source stored per target
- id
- UniProt accession (human). Links to uniprot.org.
- gene_symbol
- Gene symbol (e.g. ITGB3).
- protein_name
- Protein name (UniProt).
- tier
- Tier 1 = PDB-anchored; Tier 1.5 = AlphaFold-confident.
- has_structure
- 1 if the target protein has a reported experimental 3D structure (PDB). This is the CORE requirement the aptamer-Kd layer is built around — filter to 1 for the structure-backed set.
- evidence_priority
- DETERMINISTIC, reproducible prioritisation (0-1) computed at build time from real harvested columns: 0.35*experimental-structure(PDB=1 / AlphaFold-only=0.3) + 0.30*Open-Targets-top-disease-score + 0.20*PREDICTED-surface-accessibility(A_surface=1) + 0.15*EV-detection(EV-Map). A transparent ranking AID, not a validation; the surface/EV terms are PREDICTIONS/DETECTIONS, not measured EV-surface exposure. Recomputable exactly from this DB.
- has_activation_state_pdb_pair
- 1 if a curated ACTIVE/INACTIVE PDB pair exists (only 11 targets).
- in_cev_map
- Detected in the EV-Map plasma-EV dataset (Rai & Greening 2025, Nat Cell Biol, 10.1038/s41556-025-01795-7) = 3,422 apt-scout targets (broad detected proteome). The EV-Map CONSERVED EV proteome is 182 proteins (42 non-EV); apt-scout matches 104 of these conserved EV-hallmark proteins as targets by gene (the other 78 are not apt-scout targets). Use the ev_hallmark_targets query for that subset. IMPORTANT: EV-Map detection means the protein is EV CARGO (present in the vesicle) — it does NOT mean surface-exposed. Rai & Greening 2025 run a separate membrane-impermeant biotinylation assay giving a 151-protein SURFACEOME, and show the conserved SDCBP/syntenin is luminal (not surface-accessible). For genuine EV-surface accessibility use that 151-protein set, not EV-Map presence.
- has_known_aptamer
- 1 if PubMed '(gene) AND (aptamer OR SELEX)' returned any hit (KEYWORD co-mention, includes false positives — NOT a verified aptamer). For verified aptamers with Kd, see the Binding-affinities (v_kd) layer.
- opentargets_top_disease_score
- Open Targets association score (0-1).
- aptamer_count_pubmed
- Number of PubMed hits for (this protein) AND (aptamer OR SELEX). Keyword co-occurrence — verify each (many co-mention without a real aptamer).
- aptamer_pmids
- The actual PubMed IDs behind the aptamer evidence — click each to read the paper. This is the source of the 'has aptamer' claim.
- surface_class
- PREDICTED membrane topology (HPA-derived, not a measurement): A_surface = integral/ecto cell-surface (predicted EV-surface accessible); A2_pm_peripheral = plasma-membrane cytoplasmic-leaflet (SRC/LYN/RHOA, predicted not reachable); A_assoc = secreted/corona; B_cargo = luminal cargo; unknown = no HPA localization. Lipid asymmetry can partially flip (PS via scramblase); confirm by protease-protection / intact-EV surface labelling. See v_surface_targets.
144 rows where has_known_aptamer = 1, in_cev_map = 0 and surface_class = "A_surface" sorted by evidence_priority descending
This data as json, CSV (advanced)
Suggested facets: aptamer_count_pubmed
surface_class 1
- A_surface · 144 ✖
in_cev_map 1
- - · 144 ✖
has_known_aptamer 1
- 1 · 144 ✖
has_activation_state_pdb_pair 1
- 0 144
| id | gene_symbol | protein_name | tier | evidence_priority ▲ | has_structure | surface_class | pdb_count_total | alphafold_mean_pLDDT | has_cryoEM | has_activation_state_pdb_pair | activation_state_pdb_active | activation_state_pdb_inactive | has_known_aptamer | aptamer_count_pubmed | aptamer_pmids | in_cev_map | opentargets_top_disease_name | opentargets_top_disease_score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P13569 | CFTR | Cystic fibrosis transmembrane conductance regulator | Tier 1 | 0.824 | 1 | A_surface | 58 | 75.62 | 1 | 0 | 1 | 10 | 41148207, 31029337, 30595527, 22483890, 15657417 | 0 | cystic fibrosis | 0.9133535862571094 | ||
| P07949 | RET | Proto-oncogene tyrosine-protein kinase receptor Ret | Tier 1 | 0.809 | 1 | A_surface | 34 | 78.81 | 1 | 0 | 1 | 83 | 41962371, 41744190, 41636718, 41526122, 41406741, 41171123, 41082837, 41060784, 41027166, 40932619, 40815127, 40711581, 40633058, 40602121, 40410423, 40285964, 40252505, 40222299, 39344894, 39288589, 39190775, 38953438, 38876068, 38852325, 38718747, 38604287, 38354543, 38282384, 38237282, 37851382, 37774402, 37757695, 37437453, 37245460, 36952259, 36315022, 35550937, 35420408, 34342436, 34132907, 34016094, 33513536, 33462661, 33119785, 33011620, 32760976, 32527800, 32212604, 32138930, 31897454 | 0 | medullary thyroid gland carcinoma | 0.8617460262224842 | ||
| Q12809 | KCNH2 | Voltage-gated inwardly rectifying potassium channel KCNH2 | Tier 1 | 0.806 | 1 | A_surface | 23 | 62.75 | 1 | 0 | 1 | 1 | 22617876 | 0 | Romano-Ward syndrome | 0.8549238933917284 | ||
| P31785 | IL2RG | Cytokine receptor common subunit gamma | Tier 1.5 | 0.804 | 1 | A_surface | 14 | 75.5 | 1 | 0 | 1 | 2 | 30800133, 33869115 | 0 | gamma chain deficiency | 0.8469997000418428 | ||
| P08100 | RHO | Rhodopsin | Tier 1.5 | 0.804 | 1 | A_surface | 4 | 88.75 | 1 | 0 | 1 | 45 | 41963275, 41924874, 41636061, 40808302, 40642289, 40330320, 40045571, 39863313, 39788632, 38070612, 37191882, 36705086, 36696850, 36095194, 36049339, 35622174, 34709779, 34471566, 32696702, 32479610, 32319623, 32119944, 31737572, 31588238, 31535128, 29570714, 29281176, 28648779, 27893356, 25645980, 23757206, 23701883, 25033804, 22689339, 22302221, 22121695, 19766091, 19389625, 16419035, 12123800, 8743323, 7678562, 19188685, 18230760 | 0 | retinitis pigmentosa | 0.8481942240861982 | ||
| P07911 | UMOD | Uromodulin | Tier 1 | 0.803 | 1 | A_surface | 10 | 82.94 | 1 | 0 | 1 | 4 | 37533140, 35446786 | 0 | familial juvenile hyperuricemic nephropathy type 1 | 0.8446536377993564 | ||
| P07333 | CSF1R | Macrophage colony-stimulating factor 1 receptor | Tier 1 | 0.802 | 1 | A_surface | 26 | 77.81 | 0 | 0 | 1 | 1 | 29277631 | 0 | leukoencephalopathy, diffuse hereditary, with spheroids 1 | 0.8391971566583056 | ||
| O95342 | ABCB11 | Bile salt export pump | Tier 1.5 | 0.801 | 1 | A_surface | 8 | 83.12 | 1 | 0 | 1 | 1 | 36313979 | 0 | progressive familial intrahepatic cholestasis type 2 | 0.8372060401943777 | ||
| P42262 | GRIA2 | Glutamate receptor 2 | Tier 1 | 0.8 | 1 | A_surface | 16 | 84.94 | 0 | 0 | 1 | 4 | 28325839, 19417060, 17929944, 17024188 | 0 | neurodevelopmental disorder with language impairment and behavioral abnormalities | 0.8328652004757138 | ||
| P16473 | TSHR | Thyrotropin receptor | Tier 1 | 0.8 | 1 | A_surface | 9 | 74.0 | 1 | 0 | 1 | 6 | 41054857, 40997970, 40588369, 38650837 | 0 | hypothyroidism due to TSH receptor mutations | 0.8327127196409464 | ||
| Q92736 | RYR2 | Ryanodine receptor 2 | Tier 1 | 0.8 | 1 | A_surface | 26 | 1 | 0 | 1 | 1 | 24130701 | 0 | catecholaminergic polymorphic ventricular tachycardia 1 | 0.8338648743498255 | |||
| P10912 | GHR | Growth hormone receptor | Tier 1.5 | 0.799 | 1 | A_surface | 9 | 58.69 | 0 | 0 | 1 | 5 | 38811951, 38477735, 31603904 | 0 | Laron syndrome | 0.8304020079647765 | ||
| Q9ULV1 | FZD4 | Frizzled-4 | Tier 1 | 0.795 | 1 | A_surface | 11 | 84.31 | 1 | 0 | 1 | 1 | 18673242 | 0 | Familial exudative vitreoretinopathy | 0.8152111103672746 | ||
| Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | Tier 1 | 0.795 | 1 | A_surface | 7 | 62.0 | 1 | 0 | 1 | 2 | 25870409, 25558474 | 0 | Autosomal recessive early-onset inflammatory bowel disease | 0.8151052076044897 | ||
| Q01974 | ROR2 | Tyrosine-protein kinase transmembrane receptor ROR2 | Tier 1 | 0.794 | 1 | A_surface | 6 | 68.31 | 0 | 0 | 1 | 2 | 41782379, 18673242 | 0 | autosomal recessive Robinow syndrome | 0.8145559265435566 | ||
| Q9UM73 | ALK | ALK tyrosine kinase receptor | Tier 1 | 0.791 | 1 | A_surface | 79 | 68.19 | 0 | 0 | 1 | 6 | 40347134, 38604287, 32218299, 29205808, 24116381, 21281497 | 0 | neuroblastoma | 0.8016889264946979 | ||
| Q4KMG0 | CDON | Cell adhesion molecule-related/down-regulated by oncogenes | Tier 1 | 0.79 | 1 | A_surface | 3 | 62.03 | 0 | 0 | 1 | 3 | 36333824, 24629635, 18698484 | 0 | holoprosencephaly | 0.800378039564866 | ||
| P16410 | CTLA4 | Cytotoxic T-lymphocyte protein 4 | Tier 1.5 | 0.787 | 1 | A_surface | 22 | 80.12 | 0 | 0 | 1 | 26 | 41907643, 40972397, 40870970, 40811947, 40536609, 39417693, 38473398, 38158454, 36966395, 36831533, 36603108, 36015348, 33970170, 32929022, 32840510, 32280743, 32024070, 31405808, 28918052, 28082399, 26030229, 25565435, 24892807, 23460536, 23460531, 14612549 | 0 | autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiency | 0.7906408646569979 | ||
| P22223 | CDH3 | Cadherin-3 | Tier 1 | 0.786 | 1 | A_surface | 19 | 76.75 | 0 | 0 | 1 | 1 | 41304780 | 0 | EEM syndrome | 0.7851776755128059 | ||
| Q96MS0 | ROBO3 | Roundabout homolog 3 | Tier 1.5 | 0.784 | 1 | A_surface | 3 | 63.69 | 0 | 0 | 1 | 2 | 32369590 | 0 | horizontal gaze palsy with progressive scoliosis | 0.7813306356858872 | ||
| P43220 | GLP1R | Glucagon-like peptide 1 receptor | Tier 1 | 0.78 | 1 | A_surface | 70 | 81.5 | 1 | 0 | 1 | 2 | 40691365, 30957581 | 0 | type 2 diabetes mellitus | 0.7667004144705459 | ||
| P51654 | GPC3 | Glypican-3 | Tier 1.5 | 0.779 | 1 | A_surface | 4 | 75.06 | 1 | 0 | 1 | 65 | 42083729, 41790019, 41653459, 41045695, 40825648, 40722645, 39998646, 39874791, 39608318, 39427046, 38910291, 38787447, 38621313, 38368644, 37665421, 36903516, 36457288, 36317566, 36072763, 35788872, 35699181, 35477501, 35051745, 34974867, 34306031, 33254049, 33080969, 32356075, 30347351, 30122918, 29675356, 29605994, 29277631, 27601357, 28263753 | 0 | Simpson-Golabi-Behmel syndrome type 1 | 0.762708583613362 | ||
| P20023 | CR2 | Complement receptor type 2 | Tier 1.5 | 0.776 | 1 | A_surface | 9 | 74.94 | 1 | 0 | 1 | 1 | 33235290 | 0 | immunodeficiency, common variable, 7 | 0.7543125403898414 | ||
| P26678 | PLN | Phospholamban | Tier 1 | 0.775 | 1 | A_surface | 7 | 81.88 | 0 | 0 | 1 | 9 | 39536855, 32382487, 30777430, 25240642, 21848510, 19158349 | 0 | hypertrophic cardiomyopathy | 0.750557685745381 | ||
| Q9HBE5 | IL21R | Interleukin-21 receptor | Tier 1 | 0.775 | 1 | A_surface | 6 | 64.12 | 0 | 0 | 1 | 2 | 30800133, 29244152 | 0 | Cryptosporidiosis - chronic cholangitis - liver disease | 0.7501392499286187 | ||
| Q9Y6Q6 | TNFRSF11A | Tumor necrosis factor receptor superfamily member 11A | Tier 1 | 0.775 | 1 | A_surface | 1 | 58.91 | 0 | 0 | 1 | 1 | 15562003 | 0 | Osteopetrosis - hypogammaglobulinemia | 0.7487328542164448 | ||
| P04035 | HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Tier 1 | 0.774 | 1 | A_surface | 24 | 75.31 | 1 | 0 | 1 | 1 | 36470581 | 0 | Hypercholesterolemia | 0.7460937406970991 | ||
| P40126 | DCT | L-dopachrome tautomerase | Tier 1.5 | 0.774 | 1 | A_surface | 1 | 89.12 | 0 | 0 | 1 | 1 | 27245069 | 0 | oculocutaneous albinism type 8 | 0.7468868816172217 | ||
| P51681 | CCR5 | C-C chemokine receptor type 5 | Tier 1 | 0.773 | 1 | A_surface | 25 | 85.38 | 1 | 0 | 1 | 23 | 36576612, 33981364, 29678881, 29556342, 29301363, 27807347, 27652575, 26965267, 25794434, 25754473, 25329893, 23629001, 22811524, 21576818, 18799178, 16631118, 16227301, 15813986, 14610191, 12498773 | 0 | HIV infection | 0.7442590579227027 | ||
| Q9NR97 | TLR8 | Toll-like receptor 8 | Tier 1 | 0.771 | 1 | A_surface | 39 | 86.12 | 0 | 0 | 1 | 4 | 40085160, 39956743 | 0 | immunodeficiency 98 with autoinflammation, X-linked | 0.7360623201088097 | ||
| P21860 | ERBB3 | Receptor tyrosine-protein kinase erbB-3 | Tier 1 | 0.77 | 1 | A_surface | 23 | 72.44 | 1 | 0 | 1 | 9 | 40851486, 33770580, 33039492, 31846731, 31626948, 29440899, 23990977, 22733765, 18942860 | 0 | visceral neuropathy, familial, 1, autosomal recessive | 0.7335342096528644 | ||
| P08887 | IL6R | Interleukin-6 receptor subunit alpha | Tier 1.5 | 0.768 | 1 | A_surface | 10 | 77.88 | 1 | 0 | 1 | 18 | 40853309, 38152968, 37034659, 36579647, 35890412, 33590853, 33340765, 32515246, 29211023, 28929152, 26552813, 26383776, 24481022, 24440854, 23235494, 22503683, 22258147, 22094809 | 0 | rheumatoid arthritis | 0.7269057706798291 | ||
| Q00975 | CACNA1B | Voltage-dependent N-type calcium channel subunit alpha-1B | Tier 1.5 | 0.767 | 1 | A_surface | 7 | 59.91 | 1 | 0 | 1 | 2 | 31118475, 25782368 | 0 | Seizure | 0.7217241968702018 | ||
| P47871 | GCGR | Glucagon receptor | Tier 1 | 0.766 | 1 | A_surface | 27 | 81.88 | 1 | 0 | 1 | 5 | 28775305, 23770039, 23744070 | 0 | GCGR-related hyperglucagonemia | 0.7213152740071143 | ||
| P26842 | CD27 | CD27 antigen | Tier 1 | 0.763 | 1 | A_surface | 5 | 71.69 | 0 | 0 | 1 | 3 | 39841045, 30609550, 26320067 | 0 | lymphoproliferative syndrome 2 | 0.7084378623696481 | ||
| P40225 | THPO | Thrombopoietin | Tier 1 | 0.761 | 1 | A_surface | 3 | 61.44 | 1 | 0 | 1 | 2 | 38928037, 30312735 | 0 | thrombocythemia 1 | 0.7027329039559379 | ||
| P15941 | MUC1 | Mucin-1 | Tier 1 | 0.761 | 1 | A_surface | 23 | 47.41 | 0 | 0 | 1 | 686 | 42025056, 41988862, 41954302, 41771296, 41744704, 41744190, 41657320, 41627316, 41621292, 41582516, 41535857, 41471303, 41362016, 41352919, 41346179, 41330302, 41243570, 41205458, 41185018, 41101154, 41047832, 41027169, 40682599, 40665615, 40627939, 40607530, 40590839, 40578633, 40568899, 40556592, 40504676, 40500890, 40499867, 40479828, 40432219, 40422041, 40360093, 40286646, 40274149, 40158809, 40119836, 39978149, 39910821, 39705316, 39679901, 39626346, 39579679, 39566700, 39552005, 39550818, 41997681, 41247195, 40813258, 39454542, 39454415, 39440615, 39421884, 39406784, 39256285, 39243449, 39154820, 39142532, 39136402, 39119745, 39118454, 38923850, 38912896 | 0 | tubulointerstitial kidney disease, autosomal dominant, 2 | 0.7040398435219726 | ||
| P48023 | FASLG | Tumor necrosis factor ligand superfamily member 6 | Tier 1.5 | 0.76 | 1 | A_surface | 3 | 80.19 | 0 | 0 | 1 | 1 | 16581027 | 0 | autoimmune lymphoproliferative syndrome type 1 | 0.6984292519156657 | ||
| O14788 | TNFSF11 | Tumor necrosis factor ligand superfamily member 11 | Tier 1 | 0.759 | 1 | A_surface | 2 | 79.19 | 0 | 0 | 1 | 2 | 15562003, 41226313 | 0 | osteoporosis | 0.6957850224892792 | ||
| Q9BYF1 | ACE2 | Angiotensin-converting enzyme 2 | Tier 1 | 0.758 | 1 | A_surface | 100 | 90.69 | 1 | 0 | 1 | 91 | 41716474, 41541792, 41274248, 40642289, 40333723, 40321580, 40227272, 39964138, 39923730, 39281706, 38973558, 38553521, 37932762, 37808754, 37692001, 37666993, 37385465, 37375202, 36950312, 36822303, 36714461, 36683236, 36581924, 36073793, 35972202, 35910791, 35907639, 35542182, 34876524, 34855379, 34847324, 34798263, 34696413, 34619249, 34458322, 34282416, 34248841, 34230708, 34230707, 34166652, 34123223, 33684258, 33683787, 33629859, 33561300, 33389440, 32981365, 32838280, 32551560, 36288301, 36170362, 35748608, 34953639 | 0 | COVID-19 | 0.6925739512122528 | ||
| P15391 | CD19 | B-lymphocyte antigen CD19 | Tier 1.5 | 0.755 | 1 | A_surface | 4 | 62.22 | 1 | 0 | 1 | 13 | 41079126, 40652441, 38661725, 38148412, 36095289, 35829681, 34680368, 34364920, 32401486, 31912987, 29928472, 21127492 | 0 | immunodeficiency, common variable, 3 | 0.6821072538733047 | ||
| P32970 | CD70 | CD70 antigen | Tier 1.5 | 0.75 | 1 | A_surface | 1 | 83.19 | 0 | 0 | 1 | 1 | 30609550 | 0 | severe combined immunodeficiency due to CD70 deficiency | 0.6651491980619259 | ||
| Q96RJ3 | TNFRSF13C | Tumor necrosis factor receptor superfamily member 13C | Tier 1.5 | 0.748 | 1 | A_surface | 8 | 63.03 | 1 | 0 | 1 | 1 | 23470998 | 0 | immunodeficiency, common variable, 4 | 0.660711678987284 | ||
| Q9HCK4 | ROBO2 | Roundabout homolog 2 | Tier 1.5 | 0.744 | 1 | A_surface | 6 | 67.38 | 0 | 0 | 1 | 2 | 40616090, 31640794 | 0 | familial vesicoureteral reflux | 0.6460375744556555 | ||
| P48551 | IFNAR2 | Interferon alpha/beta receptor 2 | Tier 1 | 0.743 | 1 | A_surface | 9 | 64.44 | 0 | 0 | 1 | 1 | 35212764 | 0 | COVID-19 | 0.6417504201511338 | ||
| P21554 | CNR1 | Cannabinoid receptor 1 | Tier 1 | 0.741 | 1 | A_surface | 32 | 71.69 | 1 | 0 | 1 | 1 | 19231809 | 0 | obesity | 0.6357831368051927 | ||
| Q15116 | PDCD1 | Programmed cell death protein 1 | Tier 1 | 0.738 | 1 | A_surface | 37 | 74.12 | 0 | 0 | 1 | 27 | 41479885, 40811947, 40758411, 39562585, 37424077, 34156677, 33904236, 33896107, 33319876, 33155587, 32574155, 32429721, 31727249, 31434881, 28912094, 28288993, 41907643, 41125194, 38158454, 37944524, 36484532, 36015348, 34861397, 34386332 | 0 | melanoma | 0.6260691959208758 | ||
| Q8NER1 | TRPV1 | Transient receptor potential cation channel subfamily V member 1 | Tier 1.5 | 0.738 | 1 | A_surface | 8 | 71.94 | 1 | 0 | 1 | 2 | 40855286, 28604222 | 0 | migraine disorder | 0.6269329225883602 | ||
| P04233 | CD74 | HLA class II histocompatibility antigen gamma chain | Tier 1 | 0.737 | 1 | A_surface | 24 | 69.94 | 1 | 0 | 1 | 1 | 30899255 | 0 | non-small cell lung carcinoma | 0.6217636836935354 | ||
| P42658 | DPP6 | A-type potassium channel modulatory protein DPP6 | Tier 1.5 | 0.737 | 1 | A_surface | 8 | 86.69 | 1 | 0 | 1 | 1 | 41313574 | 0 | Autosomal dominant microcephaly | 0.6225938492787458 |
Advanced export
JSON shape: default, array, newline-delimited
CREATE VIEW v_targets AS
SELECT f.id, n.gene_symbol, n.protein_name, tg.tier,
-- evidence_priority: DETERMINISTIC, reproducible from real DB columns (no LLM).
-- Transparent weights over harvested evidence: structure 0.35, disease importance
-- 0.30 (Open Targets top-disease score), PREDICTED surface accessibility 0.20,
-- EV detection 0.15. A heuristic ranking aid, not a validation; surface/EV terms
-- are predictions/detections, NOT measured EV-surface exposure.
ROUND(
0.35*(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1.0
WHEN CAST(COALESCE(NULLIF(f.alphafold_mean_pLDDT,''),'0') AS REAL)>0 THEN 0.3 ELSE 0.0 END)
+ 0.30*MIN(CAST(COALESCE(NULLIF(f.opentargets_top_disease_score,''),'0') AS REAL), 1.0)
+ 0.20*(CASE sc.surface_class WHEN 'A_surface' THEN 1.0 WHEN 'A_assoc' THEN 0.5 WHEN 'A2_pm_peripheral' THEN 0.2 ELSE 0.0 END)
+ 0.15*(CASE WHEN CAST(COALESCE(f.in_cev_map,0) AS INTEGER)=1 THEN 1.0 ELSE 0.0 END)
, 3) AS evidence_priority,
(CASE WHEN CAST(COALESCE(f.pdb_count_total,'0') AS INTEGER)>0 THEN 1 ELSE 0 END) AS has_structure,
sc.surface_class,
f.pdb_count_total, f.alphafold_mean_pLDDT, f.has_cryoEM,
f.has_activation_state_pdb_pair, f.activation_state_pdb_active, f.activation_state_pdb_inactive,
f.has_known_aptamer, f.aptamer_count_pubmed, ap.aptamer_pmids,
f.in_cev_map, f.opentargets_top_disease_name, f.opentargets_top_disease_score
FROM v_target_full f
LEFT JOIN target_names n ON n.target_id=f.id
LEFT JOIN targets tg ON tg.id=f.id
LEFT JOIN target_aptamer_pmids ap ON ap.target_id=f.id
LEFT JOIN membrane_surface_class sc ON sc.target_id=f.id;